

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**NB**

**自然美**

**NATURAL BEAUTY**

**Natural Beauty Bio-Technology Limited**

**自然美生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00157)**

**SUPPLEMENTAL ANNOUNCEMENT  
INSIDE INFORMATION  
PROFIT WARNING**

This announcement is made by Natural Beauty Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the Company’s profit warning announcement dated 19 July 2022 in respect of the Group’s unaudited consolidated interim results for the six months ended 30 June 2022 (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

The Board wishes to update the Shareholders and potential investors that based on the preliminary assessment of the latest unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and the latest information available to the management of the Group, the Group is expected to record a net loss of approximately HK\$30.2 million for the six months ended 30 June 2022. The increase of HK\$6.6 million in the amount of expected net loss as compared to the figure previously announced in the Announcement is primarily attributable to an impairment loss on the goodwill, property, plant and equipment owing to the cessation of business of the cash generating unit (“**CGU**”) of medical aesthetics services operated by Beijing Jiayun Medical Beauty Clinic Company Limited, one of the subsidiaries of the Group due to an unsuccessful renewal of its practice license of medical institution in the PRC, which came to

the notice of the management of the Group subsequent to the publication of the Announcement. The revenue contributed by Beijing Jiayun Medical Beauty Clinic Company Limited for the six months ended 30 June 2021 and 2022 was HK\$4.5 million and HK\$2.6 million respectively, representing 1.9% and 1.6% of the total revenue of the Group for the six months ended 30 June 2021 and 2022, respectively. Therefore, the Board is of the view that the unsuccessful renewal of the practice licence of medical institution does not materially affect the business and financial performance of the Group as a whole.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2022. The information contained in this announcement is only based on a preliminary assessment by the Board of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Company, which has not been reviewed by the Company's auditors or reviewed by the audit committee of the Company and may be, subject to further adjustments. Shareholders and potential investors are advised to read carefully the results announcement of the unaudited interim results of the Group for the six months ended 30 June 2022, which is expected to be published in August 2022 pursuant to the requirements of the Listing Rules.

By order of the Board  
**Natural Beauty Bio-Technology Limited**  
**LEI Chien**  
*Chairperson*

Hong Kong, 29 July 2022

*As at the date of this announcement, the Board comprises Dr. Lei Chien and Mr. Pan Yi-Fan as executive directors; Ms. Lu Yu-Min, Ms. Lin Shu-Hua and Mr. Chen Shou-Huang as non-executive directors; and Mr. Chen Ruey-Long, Mr. Lu Chi-Chant and Mr. Yang Shih-Chien as independent non-executive directors.*